Shots:

• Following the approval from the Drug Controller General of India (DCGI), Glenmark has introduced the first biosimilar of Liraglutide under the brand name Lirafit (1.2mg, per day) for managing type 2 diabetes mellitus in India
• Lirafit gained approval based on a 24wks. study in type 2 diabetes mellitus Indian adult patients which showed its effectiveness, safety, and good tolerance. Its efficacy and safety profile were found to be non-inferior to the reference liraglutide
• The reference drug, Liraglutide, is a GLP‐1 receptor agonist that enhances glucose-dependent insulin secretion and reduces inappropriate glucagon secretion in adult patients. It is approved in both the US and the EU

Ref: Glenmark | Image: Glenmark

Related News:- Cosmo Signs a Distribution and License Agreement with Glenmark for Winlevi in Europe and South Africa

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com